Maze Therapeutics, Inc. (NASDAQ: MAZE) is a Healthcare company (Biotechnology) with a market capitalization of $1.8B. The Maz Rating grades it against the other companies in its sector.
Maze Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $32.87, Maze Therapeutics, Inc. trades at 89.4x sales and 4.6x book value. Over the last twelve months it generated about $20M of revenue and a net loss of $158M. It runs a gross margin of 95.3%, an operating margin of -820.8% and a net margin of -757.4%. It shows return on equity of -38.4%, return on invested capital of -33.6% and a free cash flow yield of -6.4%. On the balance sheet: a debt-to-equity ratio of 0.14 and a current ratio of 14.14. Over the past 52 weeks the share price ranged from $21.95 to $53.65, with a beta of 2.03.
Maze Therapeutics, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.